Skip to main content
TipRanks
Go Ultimate75% OFF

Damora Therapeutics (DMRA) Ratios

345 Followers

Damora Therapeutics Ratios

DMRA's free cash flow for Q3 2026 was $-17.23M. For the 2026 fiscal year, DMRA's free cash flow was increased by $0.00 and operating cash flow was $-17.23M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio12.9814.076.315.7524.23
Quick Ratio12.9814.076.315.7524.23
Cash Ratio12.8411.843.682.9513.77
Solvency Ratio-10.41-7.99-6.36-5.35-10.28
Operating Cash Flow Ratio-0.34-15.56-6.33-3.87-11.51
Short-Term Operating Cash Flow Coverage0.00-1551.920.000.000.00
Net Current Asset Value$ 240.28M$ 14.18M$ 30.88M$ 52.48M$ 105.11M
Leverage Ratios
Debt-to-Assets Ratio0.000.080.010.010.01
Debt-to-Equity Ratio0.000.100.010.010.01
Debt-to-Capital Ratio0.000.090.010.010.01
Long-Term Debt-to-Capital Ratio0.000.090.000.000.00
Financial Leverage Ratio1.081.181.181.191.04
Debt Service Coverage Ratio0.00-1771.500.00-145.600.00
Interest Coverage Ratio0.000.000.00-146.780.00
Debt to Market Cap0.000.250.000.000.00
Interest Debt Per Share0.051.240.231.200.84
Net Debt to EBITDA1.230.600.600.531.19
Profitability Margins
Gross Profit Margin0.00%0.00%0.00%0.00%0.00%
EBIT Margin0.00%0.00%0.00%0.00%0.00%
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
Operating Profit Margin0.00%0.00%0.00%0.00%0.00%
Pretax Profit Margin0.00%0.00%0.00%0.00%0.00%
Net Profit Margin0.00%0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin0.00%0.00%0.00%0.00%0.00%
Net Income Per EBT100.02%100.19%100.00%100.00%100.00%
EBT Per EBIT99.49%126.64%96.10%100.68%99.09%
Return on Assets (ROA)-80.54%-125.14%-100.32%-84.20%-42.35%
Return on Equity (ROE)-87.29%-148.15%-118.61%-99.79%-44.15%
Return on Capital Employed (ROCE)-87.69%-106.04%-123.17%-98.59%-44.38%
Return on Invested Capital (ROIC)-87.69%-105.96%-122.48%-97.84%-44.23%
Return on Tangible Assets-80.54%-125.14%-100.32%-84.20%-42.35%
Earnings Yield-669.07%-398.44%-200.45%-210.89%-67.61%
Efficiency Ratios
Receivables Turnover0.000.000.000.000.00
Payables Turnover0.000.480.000.000.00
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover0.000.000.000.000.00
Asset Turnover0.000.000.000.000.00
Working Capital Turnover Ratio0.000.000.000.000.00
Cash Conversion Cycle0.00-760.250.000.000.00
Days of Sales Outstanding0.000.000.000.000.00
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding0.00760.250.000.000.00
Operating Cycle0.000.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-4.93-16.09-34.73-42.24-51.77
Free Cash Flow Per Share-4.93-16.09-34.73-42.43-51.99
Dividend Paid and CapEx Coverage Ratio0.000.000.00-219.04-234.57
Capital Expenditure Coverage Ratio0.000.000.00-219.04-234.57
Operating Cash Flow Coverage Ratio-98.91-13.00-148.24-53.40-61.76
Operating Cash Flow to Sales Ratio0.000.000.000.000.00
Free Cash Flow Yield-21.45%-346.10%-192.93%-147.60%-68.63%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-0.15-0.25-0.50-0.47-1.48
Price-to-Sales (P/S) Ratio0.000.000.000.000.00
Price-to-Book (P/B) Ratio0.130.370.590.470.65
Price-to-Free Cash Flow (P/FCF) Ratio-4.66-0.29-0.52-0.68-1.46
Price-to-Operating Cash Flow Ratio-4.66-0.29-0.52-0.68-1.46
Price-to-Earnings Growth (PEG) Ratio-0.000.010.01-0.02-0.03
Enterprise Value Multiple1.080.350.060.05-0.29
Enterprise Value-226.19M-7.36M-2.08M-2.76M14.83M
EV to EBITDA1.080.350.060.05-0.29
EV to Sales0.000.000.000.000.00
EV to Free Cash Flow33.630.400.060.06-0.28
EV to Operating Cash Flow33.630.400.060.06-0.28
Tangible Book Value Per Share176.3612.5130.4260.76116.01
Shareholders’ Equity Per Share176.3612.5130.4260.76116.01
Tax and Other Ratios
Effective Tax Rate-0.00-0.000.000.000.00
Revenue Per Share0.000.000.000.000.00
Net Income Per Share-153.95-18.53-36.08-60.63-51.22
Tax Burden1.001.001.001.001.00
Interest Burden1.001.001.051.010.99
Research & Development to Revenue0.000.000.000.000.00
SG&A to Revenue0.000.000.000.000.00
Stock-Based Compensation to Revenue0.000.000.000.000.00
Income Quality0.030.870.960.701.01

Currency in USD